Recombinant annexin-2 inhibits the progress of diabetic nephropathy in a diabetic mouse model via recovery of hypercoagulability

Summary

Diabetic nephropathy, a major complication of diabetes mellitus that leads to mortality, has been shown to involve a dysregulation of the coagulation system. Annexin-2, a co-receptor for plasminogen and tissue plasminogen activator on endothelial cells, is one of the molecules required to maintain the antithrombogenic properties of endothelial cells. Previously, we showed that recombinant annexin-2 protein (rAN II) modulated impaired fibrinolytic activity in the carotid arteries of rats. In the present study, to investigate its protective effects against diabetic nephropathy, rAN II was administered to KK-Ay mice, a murine model of type 2 diabetes, for eight weeks, and albuminuria, kidney size, and histological glomerular lesions were investigated. The mean weight of kidneys from KK-Ay mice treated with rAN II was significantly less than that of those treated with PBS (control) (p<0.02). Furthermore, the level of albuminuria observed in rAN II-treated KK-Ay mice was significantly less than that of the control group (rAN II, 0.90+/-0.12 µg/day; PBS, 1.55+/-0.31 µg/day; p<0.01); also, the area of diffuse glomerular lesions was significantly smaller (rAN II, 41.51+/-4.54%; PBS, 81.81+/-8.10%; p<0.01). Bleeding time, prothrombin time (PT), and active partial thromboplastin time (APTT) did not significantly differ between the two groups. Our results suggest that rAN II may inhibit the progression of diabetic nephropathy in KK-Ay mice without influencing the coagulation system, indicating that annexin-2 may be considered as a possible new therapeutic tool for patients with diabetic nephropathy.

Keywords

Annexins - hypercoagulability - endothelial cells - diabetes mellitus

• References

• 1 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86.
• 2 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
• 3 Bergstrom J. Discovery and rediscovery of low protein diet. Clin Nephrol 1984; 21: 29-35.
• 4 Parving HH, Smidt UM, Hommel E. et al Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed) 1987; 294: 1443-7.
• 5 Vukovich T, Knobl P, Teufelsbauer H. et al The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Thromb Haemost 1992; 68: 253-6.
• 6 Roshan B, Weinrauch LA, Gleason RE. et al Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease. Metabolism 2000; 49: 88-91.
• 7 Raynal P. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium-and phospholipid-binding proteins. Biochim Biophys Acta 1994; 1197: 63-93.
• 8 Swairjo MA. Annexin structure and membrane interactions: a molecular perspective. Annu Rev Biophys Biomol Struct 1994; 23: 193-213.
• 9 Hajjar KA. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J Biol Chem 1991; 266: 21962-70.
• 10 Hajjar KA, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269: 21191-7.
• 11 Ishii H, Hiraoka M, Hajjar KA. et al Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ Res 2001; 89: 1240-5.
• 12 Nakamura M. A diabetic strain of the mouse. Proc Jap Acad 1962; 38: 384-52.
• 13 Nishimura M. Breeding of mice strains for diabetes mellitus. Exp Anim 1969; 18: 147-57.
• 14 Iwatsuka H, Matsuo T, Suzuoki Z. Congenitally impaired hormone sensitivity of the adipose tissue of spontaneously diabetic mice, KK. Validity of thrifty genotype in KK mice. Diabetologia 1974; Suppl 611-6.
• 15 Iwatsuka H, Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol Jpn 1970; 17: 23-35.
• 16 Seyer-Hansen K. Renal hypertrophy in streptozotocin diabetic rats. Clin Sci Molec Med 1976; 51: 551-5.
• 17 Cortes P, Goldman J, Levin NW. Relationship between renal function and metabolic alterations in early streptozocin-induced diabetes in rats. Diabetes 1987; 36: 80-7.
• 18 Muto Y, Muto G, Masuda T. et al Effect of longterm treatment with complete Freund’s adjuvant on KK-Ay mouse, a model of non-insulin-dependent diabetes mellitus. Clin Immunol Immunopathol 1997; 83: 53-9.
• 19 Hajjar KA. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 1990; 265: 2908-16.
• 20 Kurz KD, Sandusky GE.. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
• 22 Guthrow CE, Day JF, Thorpe SR. et al Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. Proc Natl Acad Sci USA 1979; 76: 4258-61.
• 22 Cohen MP, Surma M, Ciborowski CJ. Nonenzymatic glycosylation of basement membranes: in vitro studies. Diabetes 1981; 30: 367-71.
• 23 Williams SK, Bitensky MW. Micropinocytic ingestion of glycosylated albumin by isolated microvessels: possible role in pathogenesis of diabetic microangiopathy. Proc Natl Acad Sci USA 1981; 78: 2393-7.